Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

60.15 USD -0.18 (-0.30%)
Official Closing Price Updated: 7:00 PM EDT, Sep 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,661,276
Open 60.50
Bid (Size) 60.15 (1)
Ask (Size) 60.27 (8)
Prev. Close 60.33
Today's Range 60.05 - 60.66
52wk Range 56.75 - 69.75
Shares Outstanding 2,222,113,553
Dividend Yield 3.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Country 2 Country 4 Cancer (C2C4C) Event
Tags Philanthropy & Cause Initiatives #C2C4C Health & Healthcare
From 3BL Media: Corporate Social Responsibility, Energy and Health News
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
FN Media Group Presents USA News Group News Commentary 
From PR Newswire

Performance

YTD
-2.00%
-2.00%
1 Month
-12.75%
-12.75%
3 Month
-8.78%
-8.78%
6 Month
-3.94%
-3.94%
1 Year
+4.12%
+4.12%

More News

Read More
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients w
From Business Wire News Releases
Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting
Tags Briefs ONTX Trading Ideas
From Benzinga
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenoc
From Business Wire News Releases
3 Cheap Healthcare Stocks to Buy Right Now
Tags NYSE:BMY,NYSE:NUS,NASDAQ:IRWD,NYSE:ABBV NUS IRWD
From InvestorPlace
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
Tags Movers News Biotech
From Benzinga
Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreat
From Business Wire News Releases
Gritstone Unveils "Off-The-Shelf" Neoantigen Immunotherapy Data In Lung Cancer
Tags Trading Ideas Phase 1 Trial Market News
From Benzinga
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
Tags Movers GRTS General
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.